Drugs Used in Congestive Heart Failure (CHF)

• Drugs Used in Congestive Heart Failure (CHF) include diuretics, ACE inhibitors, beta-blockers, and digitalis to improve heart function.
• Understanding Drugs Used in Congestive Heart Failure (CHF) is vital for symptom relief, slowing disease progression, and enhancing survival.
• Congestive heart failure is a clinical syndrome where the heart is unable to pump sufficient blood to meet the body’s metabolic demands.
• The main goals in pharmacotherapy are to improve hemodynamics, reduce cardiac workload, and prevent disease progression.

Major Classes of Anti-Hyperlipidemic Drugs

1. Diuretics

• Mechanism of Action

  • Reduce blood volume by promoting urinary excretion of sodium and water, thereby decreasing preload.

• Common Classes

  • Loop Diuretics (e.g., Furosemide): Potent diuresis by inhibiting the Na+^++-K+^++-2Cl−^-− cotransporter in the thick ascending limb of the loop of Henle.
  • Thiazide Diuretics (e.g., Hydrochlorothiazide): Inhibit Na+^++-Cl−^-− cotransporter in the distal convoluted tubule.
  • Potassium-Sparing Diuretics (e.g., Spironolactone): Aldosterone receptor antagonists in the collecting ducts → Prevent K+^++ loss and Na+^++ reabsorption.

• Therapeutic Effects

  • Decreased preload → Reduced pulmonary congestion and edema → Symptomatic relief.
  • Spironolactone/Eplerenone also counteracts cardiac remodeling due to aldosterone.

2. ACE Inhibitors and ARBs

• ACE Inhibitors (e.g., Enalapril, Lisinopril)

  • Inhibit the angiotensin-converting enzyme, preventing formation of Angiotensin II.
  • Result: Vasodilation (↓ afterload), decreased aldosterone release (↓ preload), and slowed pathologic cardiac remodeling.

• ARBs (e.g., Losartan, Valsartan)

  • Block angiotensin II type-1 receptors.
  • Similar hemodynamic and protective effects to ACE inhibitors but avoid the cough side effect (caused by bradykinin accumulation in ACE inhibitors).

3. Beta-Blockers

• Examples

  • Carvedilol, Metoprolol, Bisoprolol.

• Mechanism

  • Inhibit excessive sympathetic drive → Decrease heart rate and contractility over the long term → Reduce oxygen demand and slow progression of HF.
  • Protect against catecholamine-induced toxicity and arrhythmias.

• Clinical Notes

  • Must be started at low doses and titrated slowly due to negative inotropic effect.
  • Long-term use improves survival and reduces hospitalizations.

4. Positive Inotropes

1. Digoxin

   • Inhibits Na+^++-K+^++-ATPase → ↑ Intracellular Na+^++ → ↑ Intracellular Ca2+^{2+}2+ (via the Na+^++-Ca2+^{2+}2+ exchanger) → Enhanced contractility.
   • Also decreases AV nodal conduction (useful for rate control in atrial fibrillation).
   • Narrow therapeutic index; watch for toxicity (arrhythmias, visual changes, GI upset).

2. Other Inotropes (e.g., Dobutamine, Milrinone in acute setting)

   • Dobutamine: β1_11​ agonist → ↑ Contractility, modest ↑ HR.
   • Milrinone: Phosphodiesterase-3 inhibitor → ↑ cAMP → ↑ Ca2+^{2+}2+ influx → Positive inotropy and vasodilation.

5. Vasodilators

• Hydralazine + Isosorbide Dinitrate

  • Hydralazine: Arteriolar dilator → ↓ Afterload.
  • Isosorbide Dinitrate: Venodilator → ↓ Preload.
  • Particularly beneficial in certain patient populations (e.g., African American patients with HF).

Clinical Considerations:

• Combination Therapy: Often necessary for optimal management.
• Monitoring: Regular assessment of renal function, electrolytes, and heart function.
• Individualization: Tailoring therapy based on patient-specific factors.

Thank you for reading from Firsthope's notes, don't forget to check YouTube videos!